DCPH Oct 2024 25.000 call(CONTR
| Previous Close | 0.6300 |
| Open | 0.6500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.6300 - 0.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 19 |
Business WireDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
WALTHAM, Mass., June 03, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, and
ZacksHere's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
Deciphera Pharmaceuticals (DCPH) delivered earnings and revenue surprises of 5.45% and 2.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
